Can peptide serums make your hair fall out?

There is no published signal that they do. On 26 October 2026 PubMed held no report linking hair loss to the common skincare peptides such as Argireline or Matrixyl, and the copper-peptide hair literature studies them as a treatment for thinning, not a cause of it. Shedding that starts after a new product is more often a coincidence of timing, but a dermatologist can tell the types of hair loss apart.

Why do some peptide injections list hair loss as a side effect?

The clearest case is the weight-loss drugs. Their labels report hair loss more often than placebo, and Zepbound's label ties it to weight reduction. Losing weight quickly is a recognised trigger for telogen effluvium, a temporary shedding that shows up weeks to months after the trigger. Other peptide drugs list it for their own reasons: leuprolide, a hormone-suppressing drug, lists alopecia among its effects.

Is hair loss from Ozempic or Zepbound permanent?

The labels do not say it is, and shedding of the telogen-effluvium type usually recovers once the trigger settles. The labels do not report follow-up of hair regrowth, though, so how often it fully recovers on these drugs is not established on the label. GLP1 Ledger's hair-loss page covers the drug-specific studies; anyone on one of these medicines should raise new shedding with the prescriber.

Do research peptides like BPC-157 or GHK-Cu injections cause hair loss?

Nobody has published data either way. PubMed held no record joining BPC-157 with hair loss on 26 October 2026, and injectable copper peptide has no registered safety trial that would capture it. The absence of reports for unapproved compounds means the question has not been studied, not that the answer is no.

Do peptides help with hair loss instead?

A few have small trials, mostly sponsored by the companies that make them, and none is approved as a hair-loss treatment. The established treatments, minoxidil and finasteride, have far larger trial records. Our peptides for hair growth page counts the trials side by side.

Why does hair loss affect women more on these drugs?

Zepbound's label reports 7.1% of women against 0.5% of men in its pooled weight trials, and 1.3% against 0% on placebo, so the difference appeared in both groups. The label gives the figures without an explanation; possible reasons discussed in the literature include differences in how hair loss is noticed and reported and in baseline hair-cycle sensitivity.

Do Peptides Cause Hair Loss? What Drug Labels, Trials and Skincare Studies Record

Some peptide medicines list hair loss on their FDA labels, mostly as shedding that tracks fast weight loss. Cosmetic peptides in serums and shampoos have no published hair-loss signal. A label-by-label census, dated.

"Do peptides cause hair loss?" is really three questions, because the word peptide covers three very different things: prescription peptide drugs injected weekly or daily, research compounds sold online, and cosmetic peptides in serums and shampoos. They have very different records. This page sets out what each one's record shows, from FDA labels, trial registries and PubMed, as read on 26 October 2026.

The short answer

Some peptide medicines list hair loss on their labels, most clearly the weight-loss drugs, where it is reported more often than on placebo and is tied to weight reduction.
Cosmetic peptides have no published hair-loss signal. The copper-peptide hair literature studies them as a treatment for thinning.
Unapproved research peptides have no data at all, which is a gap, not a reassurance.

Peptide medicines: a label census

We read the current FDA labels of eleven peptide medicines through openFDA and searched each for "hair loss" and "alopecia". The table gives what each label says, in the label's own category.

Medicine (peptide)	Label date read	What the label says about hair
Zepbound (tirzepatide)	28 Aug 2026	Hair loss 4–5% across doses vs 1% placebo; "associated with weight reduction"; 7.1% of women vs 0.5% of men
Wegovy (semaglutide 2.4 mg)	23 Apr 2024	Hair loss 3% (n = 2,116) vs 1% placebo (n = 1,261) in adults; 4% vs 0% in the adolescent trial
Saxenda (liraglutide)	25 Feb 2026	Alopecia among post-approval reports
Mounjaro (tirzepatide, diabetes)	29 Jul 2026	Alopecia among post-approval reports
Ozempic (semaglutide, diabetes)	30 Jan 2026	Alopecia among post-approval reports
Lupron Depot (leuprolide)	18 Sep 2025	Alopecia and "hair disorder" among reported effects; "androgen-like effects (acne, alopecia)" in its trial table
Sandostatin (octreotide)	22 Jul 2026	Hair loss in a list of less common reactions
Forteo (teriparatide)	3 Aug 2026	No mention
Egrifta (tesamorelin)	29 Jul 2026	No mention
Vyleesi (bremelanotide)	13 Nov 2025	No mention
Scenesse (afamelanotide)	11 May 2026	No mention

Seven of eleven mention it; four do not. The categories matter. A trial-table figure such as Zepbound's is a measured rate against placebo. A post-approval listing, as on Saxenda, Mounjaro and Ozempic, means reports were received after the drug went on sale; the labels say such reports come from a population of uncertain size, so a frequency or a cause cannot be established from them.

Why the weight-loss drugs lead the table

Zepbound's label states the mechanism it observed in plain words: hair loss in tirzepatide-treated patients "was associated with weight reduction". No tirzepatide-treated patient in those trials stopped treatment because of it; one placebo patient did.

Rapid weight loss is a recognised trigger of telogen effluvium, a temporary shedding in which a shock to the body pushes many follicles into their resting phase at once; the shedding usually shows some weeks to months after the trigger. PubMed holds 706 records with the term in the title or abstract; 18 also name a GLP-1 drug, and every one of those 18 was published from 2024 onward, including cohort studies from the TriNetX health-record network and several systematic reviews. The drug-specific detail, including how these medicines compare with each other and with bariatric surgery, belongs to GLP1 Ledger's hair loss page, which this page does not try to repeat.

The other drugs on the list have their own reasons. Leuprolide suppresses sex hormones, and hair is hormone-sensitive. Octreotide, a somatostatin analogue, lists hair loss among a long run of less common reactions without a stated mechanism.

Cosmetic peptides: no signal in the record

For the peptides in serums, creams and shampoos, the published record runs the other way.

PubMed returned 0 records joining hair loss or alopecia with Argireline, acetyl hexapeptide-8, Matrixyl or palmitoyl pentapeptide on 26 October 2026.
The 8 records joining hair loss with copper peptides (GHK, copper tripeptide) read by title, all concern them as a treatment for thinning: a 2016 Korean study pairing GHK with aminolevulinic acid, injected growth-factor formulations, laser-assisted delivery, a 2026 microneedle review and a 2026 laboratory composition for stress-related alopecia. None reports copper peptides causing shedding. The treatment side of that record, with its limits, is on our copper peptides for hair page.

No signal is not the same as proof of safety. Cosmetic peptides are rarely studied for side effects at all, and the trials that exist are small. But there is no case report, cohort or trial linking the common cosmetic peptides to hair loss, which is a different situation from the drugs above.

The copper-peptide "uglies", the temporary dull or rough patch some users describe after starting copper peptides, concern facial skin rather than hair; that claim is examined on its own copper uglies page.

Research peptides: an unanswered question

BPC-157 returned 0 PubMed records joined with hair loss or alopecia. Injectable copper peptide, TB-500 and the "glow" blends have no registered safety trial that would capture hair effects; what those blends contain is set out on our glow blend page. For compounds that have never been through approval, an empty record means nobody has looked. It cannot be read as evidence they are safe for hair, or that they are not.

If shedding starts

Hair loss has many causes, and several, including thyroid disease, iron deficiency, hormonal changes and autoimmune alopecia, look alike at first. A dermatologist can tell telogen shedding from pattern hair loss or patchy alopecia, sometimes with a simple pull test or a scalp examination. Anyone on a prescription peptide who notices new shedding should raise it with the prescriber rather than stopping or changing the medicine on their own. What the topical peptide hair products can and cannot claim is on our peptides for hair growth page, which counts their trials against minoxidil and finasteride.

Sources

Opened 26 October 2026: openFDA drug-label records for Zepbound (set id 487cd7e7…, effective 2026-08-28), Wegovy (f5e548d0…, 2024-04-23), Saxenda (3946d389…, 2026-02-25), Mounjaro (0818426a…, 2026-07-29), Ozempic (27f15fac…, 2026-01-30), Lupron Depot (00c486b0…, 2025-09-18), Sandostatin (4e2c9856…, 2026-07-22), Forteo (aae667c5…, 2026-08-03), Egrifta (3d783378…, 2026-07-29), Vyleesi (f1d0c1b5…, 2025-11-13) and Scenesse (94f53286…, 2026-05-11), each searched for "hair loss" and "alopecia". PubMed searches: "telogen effluvium"[tiab] (706); the same with semaglutide, tirzepatide, liraglutide or "GLP-1" (18, every title read); hair loss terms with GHK or copper peptide (8, every title read); with Argireline, acetyl hexapeptide-8, Matrixyl or palmitoyl pentapeptide (0); with BPC-157 (0). Corrections go to the contact page.